2026-04-05 01:39:14
Latest Post
Bharat Coking Coal Limited - Stoppage of Mining Operations at ABOCP Mine
Bajaj Finance Limited - Business Update Q4 FY2026
Prestige Estates Launches Mega 5,120-Unit Township 'Prestige Golden Grove' in Hyderabad with GDV of ₹9,500 Cr
Dynacons honoured with the Best Partner for Driving HPE & Nutanix Solution for the Year 2025
JK Lakshmi Cement Limited declared Preferred Bidder in the e-Auction for Chhipta Limestone Block, Madhya Pradesh
Stock Report
Aventis Pharma (Sanofi-Aventis Group) and Themis Laboratories Pvt Ltd sign Technology Transfer Deal
Posted On : 2007-07-25 22:35:23( TIMEZONE : IST )
Aventis Pharma Ltd has announced that Themis Laboratories Pvt Ltd has signed a technology transfer agreement with Adventism Parma Ltd, a member of the sanofi-aventis Group, for fixed - dose combinations comprising glibenclamide (Daonil®) and glimepiride (Amaryl®), two best selling products from the sanofi-aventis research pipeline with sustained-release metformin through a unique technology developed by Themis Laboratories for the treatment of Type 2 diabetes.
Diabetes is a major problem affecting the Indian population, with an estimated 42 million individuals suffering from this disease; these numbers are expected to rise to over 80 million by the year 2030. Earlier, both Daonil® and Amaryl® were available as single - ingredient drugs for the treatment of Type 2 diabetes. However, there was a need to introduce a fixed-dose combination for both drugs with metformin sustained-release formulation through a technology that ensures the requisite bioavailability to help patients needing such a combination therapy.
Dr. Shailesh Ayyangar, Managing Director of the Company stated, "The technology transfer agreement with Themis Laboratories has enabled Aventis Pharma to introduce Daonil® M and Amaryl® M in India to give doctors and patients access to top-quality combination products with indigenously developed patented technology of Themis Laboratories. This will widen their portfolio of drugs to manage Type 2 diabetel at various disease progression points. The new fixed-dose combination products use, on an exclusive basis, a patented technology developed by Themis Laboratories that ensures the required bio-availability of individual components and improves convenience and compliance with therapy".
The stock was trading at Rs.1315.05, down by Rs.18.30 or 1.37%. The stock hit an intraday high of Rs.1349.80 and low of Rs.1310. The total traded quantity was 3140 compared to 2 week average of 2293.
